文献速递瓣膜病与结构性心脏病血脂与心血管预防

可穿戴设备测量的中高强度体力活动与退行性主动脉瓣狭窄风险

Wearable device-measured moderate to vigorous physical activity and risk of degenerative aortic valve stenosis.
PubMed 文献 · Eur Heart J · 2025-01-01

基于英国生物银行87 248名参与者加速度计测量的中高强度体力活动(MVPA)数据,中位随访8.11年发现MVPA量越高,主动脉瓣狭窄(AS)发病及AS相关干预或死亡风险越低,约300分钟/周后趋于平缓;问卷数据二次分析结果一致。

要点

  • MVPA量增加与AS发病风险及AS相关干预或死亡风险下降相关,约300分钟/周后效应趋于平缓。
  • MVPA与主动脉瓣反流或二尖瓣反流发病关联不明显。
  • 在高血压、肥胖、血脂异常和慢性肾脏病等高危人群中,MVPA的有益关联保持一致。

核心结论

  • 较高的MVPA量与较低的AS发病风险及后续AS相关干预或死亡风险相关。

研究设计与样本

  • 主分析使用2013至2015年87 248名英国生物银行参与者整周加速度计测量的MVPA数据,中位年龄63.3岁,女性56.9%。
  • 二次分析使用2006至2010年361 681名英国生物银行参与者问卷来源的MVPA数据,中位年龄57.7岁,女性52.7%。

主要发现

  • 加速度计队列中位随访8.11年期间发生555例新发AS、201例新发AR和655例新发MR。
  • MVPA四分位(Q1-Q4)的AS调整发病率分别为11.60(10.20, 13.20)、7.82(6.63, 9.23)、5.74(4.67, 7.08)和5.91(4.73, 7.39)/10 000人年。
  • MVPA四分位(Q1-Q4)的AS相关干预或死亡调整率分别为4.37(3.52, 5.43)、2.81(2.13, 3.71)、1.93(1.36, 2.75)和2.14(1.50, 3.06)/10 000人年。
  • 问卷数据中Q4 vs Q1的AS发病率调整绝对差为-1.41(-.67, -2.14)/10 000人年,AS相关干预或死亡为-.38(-.04, -.88)/10 000人年。

临床怎么用

  • 可将提高MVPA量作为中老年人群预防退行性主动脉瓣狭窄的潜在策略,尤其在高危人群中。

局限性

  • 研究结果需在多样人群中通过更长随访时间和重复活动监测期进行验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Physical activity has proven effective in preventing atherosclerotic cardiovascular disease, but its role in preventing degenerative valvular heart disease (VHD) remains uncertain. This study aimed to explore the dose-response association between moderate to vigorous physical activity (MVPA) volume and the risk of degenerative VHD among middle-aged adults. METHODS: A full week of accelerometer-derived MVPA data from 87 248 UK Biobank participants (median age 63.3, female: 56.9%) between 2013 and 2015 were used for primary analysis. Questionnaire-derived MVPA data from 361 681 UK Biobank participants (median age 57.7, female: 52.7%) between 2006 and 2010 were used for secondary analysis. The primary outcome was the diagnosis of incident degenerative VHD, including aortic valve stenosis (AS), aortic valve regurgitation (AR), and mitral valve regurgitation (MR). The secondary outcome was VHD-related intervention or mortality. RESULTS: In the accelerometer-derived MVPA cohort, 555 incident AS, 201 incident AR, and 655 incident MR occurred during a median follow-up of 8.11 years. Increased MVPA volume showed a steady decline in AS risk and subsequent AS-related intervention or mortality risk, levelling off beyond approximately 300 min/week. In contrast, its association with AR or MR incidence was less apparent. The adjusted rates of AS incidence (95% confidence interval) across MVPA quartiles (Q1-Q4) were 11.60 (10.20, 13.20), 7.82 (6.63, 9.23), 5.74 (4.67, 7.08), and 5.91 (4.73, 7.39) per 10 000 person-years. The corresponding adjusted rates of AS-related intervention or mortality were 4.37 (3.52, 5.43), 2.81 (2.13, 3.71), 1.93 (1.36, 2.75), and 2.14 (1.50, 3.06) per 10 000 person-years, respectively. Aortic valve stenosis risk reduction was also observed with questionnaire-based MVPA data [adjusted absolute difference Q4 vs. Q1: AS incidence, -1.41 (-.67, -2.14) per 10 000 person-years; AS-related intervention or mortality, -.38 (-.04, -.88) per 10 000 person-years]. The beneficial association remained consistent in high-risk populations for AS, including patients with hypertension, obesity, dyslipidaemia, and chronic kidney disease. CONCLUSIONS: Higher MVPA volume was associated with a lower risk of developing AS and subsequent AS-related intervention or mortality. Future research needs to validate these findings in diverse populations with longer durations and repeated periods of activity monitoring.

来源:Eur Heart J,查看原文。版权归原作者所有。

引用

  1. Li Z, Cheng S, Guo B, et al. Wearable device-measured moderate to vigorous physical activity and risk of degenerative aortic valve stenosis. Eur Heart J. 2025. PMID: 38953786. doi:10.1093/eurheartj/ehae406

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。